abstract |
The present invention provides 3-(phthalazin-1-yl)benzenesulfonamide-based compounds of formula (I), Formula (I) and pharmaceutically acceptable salts thereof, which have been found to be advantageously potent and selective inhibitors of SLC16A3, as well as their use in the treatment or prevention of SLC16A3-associated diseases/disorders such as cancer. |